GBT - Global Blood Therapeutics, Inc.
| Previous Close | 76.89 |
| Open | 76.40 |
| Bid | 76.96 x 800 |
| Ask | 80.00 x 1100 |
| Day's Range | 75.32 - 77.67 |
| 52 Week Range | 34.92 - 79.95 |
| Volume | 707,120 |
| Avg. Volume | 1,077,552 |
| Market Cap | 4.6B |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.89 |
| Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 100.19 |
- MarketWatch
Biotech stocks are producing outsized gains — here’s how to get your share
An evergreen strategy is to buy stocks of companies that are likely to be bought out at attractive premiums.
- Zacks
Why Is Global Blood (GBT) Up 68.2% Since Last Earnings Report?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Insider Monkey
Did Hedge Funds Drop The Ball On Global Blood Therapeutics Inc (GBT)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on December 1, 2019, the compensation committee of GBT’s.
- TheStreet.com
Global Blood Therapeutics Is Poised to Rally Further in the Months Ahead
Global Blood Therapeutics broke out to new highs last week and remains strong today. Let's check out the charts of this clinical-stage biopharmaceutical company. In this daily bar chart of GBT, below, we can see that prices made a straight up rally in November breaking above the June 2019 highs.
- Zacks
Biotech Tops in November: Best ETFs & Stocks
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
- Zacks
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
- Zacks
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
- Zacks
Global Blood (GBT) in Focus: Stock Moves 5.2% Higher
Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.
- Zacks
Why Gold is Headed to Zero -- And What You Should Buy Instead
Why Gold is Headed to Zero -- And What You Should Buy Instead
- Zacks
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
Key highlights of the past week include regulatory and pipeline updates.
- Benzinga
The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
- Zacks
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
- Zacks
Why Biotech ETFs Surged in Monday's Trading Session
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
- Investor's Business Daily
This Biotech Broke Out Bullishly — But Couldn't Hold Onto That Gain
GBT stock briefly broke out Tuesday after Global Blood Therapeutics gained earlier-than-expected approval of a sickle cell treatment. The drug, called Oxbryta, is a once-daily tablet.
- MarketWatch
Global Blood Therapeutics stock is up on sickle cell therapy approval
Shares of Global Blood Therapeutics jumped 11% in premarket trading following the announcement Monday evening that the Food and Drug Administration had approved Oxbryta, its sickle cell disease treatment. It's the second sickle cell drug approved by the FDA this month. Novartis's Adakveo was approved by the regular on Nov. 15. The monthly wholesale acquisition cost for Adakveo is between $7,071 and $9,428; for Oxbryta, it's $10,417 per month. SunTrust Robinson Humphrey analysts forecast $69 million in sales of Oxbryta in 2020 and raised their price target to $110 from $100. Global Blood Therapeutics' stock has rallied 46% year-to-date, while the S&P 500 is up 25%.
- Benzinga
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
- GlobeNewswire
GBT Announces Participation at Upcoming Investor Conferences in December
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the following investor conferences in.
- Investor's Business Daily
Could An Earlier-Than-Expected Approval Send This Biotech Into A Breakout?
Global Blood Therapeutics gained Food and Drug Administration approval for a new sickle cell treatment on Monday, three months ahead of expectations. GBT stock surged ahead of the news.
- GlobeNewswire
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older.1 Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to be available through GBT’s specialty pharmacy partner network within two weeks.
- Reuters
UPDATE 3-FDA approves Global Blood Therapeutics sickle cell disease drug
The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. It is the second drug in recent days to win U.S. approval for sickle cell anemia, and the first to target the underlying cause of the disease rather than symptoms. Last week Novartis AG's Adakveo won U.S. regulatory clearance to reduce the incidence of sickle cell-related pain crises, a common and debilitating symptom of the disease.
- American City Business Journals
Ties to Bay Area drug companies could help (or not) this latest presidential hopeful
Serving on the board of a South San Francisco company on the cusp of a drug approval may have helped this Democratic Party candidate for president gain insight into drug pricing. It also may make him a target for other candidates.
- Zacks
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.
- Zacks
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
- GlobeNewswire
GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the third.
